PriceTargets.com logo

Fulcrum Therapeutics - FULC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.33
  • Forecasted Upside: 114.56%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.35 As of 12/20/2024 06:51 PM ET
▲ +0.32 (7.94%)

This chart shows the closing price for FULC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fulcrum Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FULC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FULC

Analyst Price Target is $9.33
▲ +114.56% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $9.33, with a high forecast of $23.00 and a low forecast of $2.00. The average price target represents a 114.56% upside from the last price of $4.35.

This chart shows the closing price for FULC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in Fulcrum Therapeutics. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$4.00 ➝ $4.00
11/14/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
9/13/2024HC WainwrightDowngradeBuy ➝ Neutral$17.00 ➝ $4.00
9/12/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
9/12/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$15.00 ➝ $4.00
9/12/2024Leerink PartnersReiterated RatingOutperform ➝ Market Perform$4.00
9/12/2024Bank of AmericaDowngradeNeutral ➝ Underperform$10.00 ➝ $2.00
9/12/2024Stifel NicolausDowngradeBuy ➝ Hold$22.00 ➝ $3.00
9/12/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral
9/9/2024Bank of AmericaUpgradeUnderperform ➝ Neutral$5.00 ➝ $10.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
7/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$23.00 ➝ $23.00
5/20/2024Cantor FitzgeraldInitiated CoverageOverweight$23.00
5/14/2024OppenheimerLower TargetOutperform ➝ Outperform$16.00 ➝ $14.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00
5/13/2024The Goldman Sachs GroupUpgradeNeutral ➝ Buy$6.00 ➝ $15.00
3/13/2024Royal Bank of CanadaInitiated CoverageOutperform$14.00
2/28/2024HC WainwrightBoost TargetBuy ➝ Buy$14.00 ➝ $17.00
2/28/2024Piper SandlerBoost TargetOverweight ➝ Overweight$13.00 ➝ $15.00
1/25/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$5.00 ➝ $6.00
9/25/2023The Goldman Sachs GroupInitiated CoverageNeutral$5.00
8/23/2023HC WainwrightUpgradeNeutral ➝ Buy$5.00 ➝ $14.00
8/22/2023OppenheimerReiterated RatingOutperform ➝ Outperform$16.00
8/22/2023Stifel NicolausUpgradeHold ➝ Buy$4.00 ➝ $11.00
8/4/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00
5/16/2023HC WainwrightLower Target$6.00 ➝ $5.00
5/4/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$9.00 ➝ $3.00
3/13/2023The Goldman Sachs GroupLower TargetBuy$17.00 ➝ $9.00
3/10/2023Morgan StanleyLower TargetEqual Weight$8.00 ➝ $7.00
3/10/2023SVB SecuritiesLower Target$18.00 ➝ $10.00
3/10/2023HC WainwrightDowngradeBuy ➝ Neutral$20.00 ➝ $6.00
3/10/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral$11.00 ➝ $8.00
3/9/2023Stifel NicolausDowngradeBuy ➝ Hold$35.00 ➝ $6.00
2/28/2023HC WainwrightReiterated RatingBuy$20.00
2/27/2023Credit Suisse GroupLower TargetOutperform$19.00 ➝ $11.00
2/27/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$27.00 ➝ $8.00
2/27/2023OppenheimerLower TargetOutperform$26.00 ➝ $20.00
2/24/2023Bank of AmericaDowngradeNeutral ➝ Underperform
1/24/2023Morgan StanleyBoost TargetOverweight$26.00 ➝ $27.00
1/23/2023Piper SandlerBoost TargetOverweight$18.00 ➝ $21.00
1/19/2023OppenheimerLower Target$30.00 ➝ $26.00
1/19/2023The Goldman Sachs GroupBoost TargetBuy$11.00 ➝ $17.00
11/15/2022OppenheimerLower Target$30.00
11/15/2022The Goldman Sachs GroupInitiated CoverageBuy$11.00
11/14/2022Morgan StanleyBoost TargetOverweight$25.00 ➝ $26.00
11/9/2022Credit Suisse GroupLower TargetOutperform$22.00 ➝ $19.00
11/8/2022Piper SandlerLower Target$42.00 ➝ $18.00
10/20/2022Stifel NicolausLower Target$43.00 ➝ $35.00
8/15/2022Credit Suisse GroupLower Target$22.00
8/12/2022HC WainwrightReiterated RatingBuy$20.00
6/10/2022HC WainwrightReiterated RatingBuy$20.00
5/27/2022Stifel NicolausReiterated RatingBuy$43.00
5/17/2022Morgan StanleyLower TargetOverweight$25.00
4/12/2022Morgan StanleyBoost TargetOverweight$25.00 ➝ $26.00
3/25/2022Credit Suisse GroupBoost TargetOutperform$30.00 ➝ $35.00
3/7/2022OppenheimerInitiated CoverageOutperform$33.00
3/4/2022HC WainwrightInitiated CoverageBuy$40.00
3/3/2022Piper SandlerLower Target$46.00 ➝ $42.00
3/3/2022Bank of AmericaUpgradeUnderperform ➝ Neutral
8/17/2021Piper SandlerBoost TargetHold ➝ Overweight$20.00 ➝ $46.00
8/17/2021HC WainwrightBoost TargetPositive ➝ Buy$20.00 ➝ $40.00
8/15/2021Leerink PartnersReiterated RatingBuy$23.00
8/13/2021Leerink PartnersBoost TargetOutperform$23.00 ➝ $37.00
8/11/2021Credit Suisse GroupBoost TargetPositive ➝ Outperform$20.00 ➝ $30.00
8/11/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$12.00 ➝ $34.00
8/10/2021Stifel NicolausBoost TargetBuy$39.00 ➝ $45.00
6/24/2021Stifel NicolausBoost TargetBuy$20.00 ➝ $39.00
4/12/2021HC WainwrightReiterated RatingBuy$20.00
3/22/2021Credit Suisse GroupInitiated CoverageOutperform$26.00
3/8/2021Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00
3/4/2021Piper SandlerLower TargetOverweight$22.00 ➝ $20.00
3/1/2021Stifel NicolausInitiated CoverageBuy$18.00
11/10/2020Leerink PartnersLower TargetOutperform$25.00 ➝ $23.00
10/15/2020Piper SandlerInitiated CoverageOverweight$22.00
8/12/2020BTIG ResearchLower Target$27.00 ➝ $22.00
8/12/2020Bank of AmericaDowngradeNeutral ➝ Underperform$11.00
8/12/2020HC WainwrightLower TargetBuy$28.00 ➝ $20.00
8/12/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$29.00 ➝ $11.00
6/19/2020Bank of AmericaDowngradeBuy ➝ Neutral$19.00 ➝ $23.00
6/17/2020Raymond JamesUpgradeMarket Perform ➝ Outperform
6/16/2020BTIG ResearchInitiated CoverageBuy$27.00
3/6/2020HC WainwrightReiterated RatingBuy$21.00 ➝ $28.00
12/24/2019HC WainwrightReiterated RatingBuy$21.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.90 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 7 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 7 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 7 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
Mentions as of
9/22/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Fulcrum Therapeutics logo
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.35
Low: $3.95
High: $4.39

50 Day Range

MA: $3.59
Low: $2.97
High: $4.54

52 Week Range

Now: $4.35
Low: $2.86
High: $13.70

Volume

2,817,768 shs

Average Volume

995,600 shs

Market Capitalization

$234.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Fulcrum Therapeutics?

The following Wall Street analysts have issued reports on Fulcrum Therapeutics in the last year: Bank of America Co., Cantor Fitzgerald, HC Wainwright, Leerink Partners, Leerink Partnrs, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for FULC.

What is the current price target for Fulcrum Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Fulcrum Therapeutics in the last year. Their average twelve-month price target is $9.33, suggesting a possible upside of 114.6%. Cantor Fitzgerald has the highest price target set, predicting FULC will reach $23.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $2.00 for Fulcrum Therapeutics in the next year.
View the latest price targets for FULC.

What is the current consensus analyst rating for Fulcrum Therapeutics?

Fulcrum Therapeutics currently has 1 sell rating, 6 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FULC, but not buy more shares or sell existing shares.
View the latest ratings for FULC.

What other companies compete with Fulcrum Therapeutics?

Other companies that are similar to Fulcrum Therapeutics include Bicara Therapeutics, Zymeworks, Gyre Therapeutics, Poseida Therapeutics and Phibro Animal Health. Learn More about companies similar to Fulcrum Therapeutics.

How do I contact Fulcrum Therapeutics' investor relations team?

Fulcrum Therapeutics' physical mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 651-8851 and its investor relations email address is [email protected]. The official website for Fulcrum Therapeutics is www.fulcrumtx.com. Learn More about contacing Fulcrum Therapeutics investor relations.